Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with: Metastatic castration-resistant prostate cancer (CRPC); Newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).